Company Encyclopedia
View More
name
Check Cap
CHEK.US
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products. The company was incorporated in 2004 and is based in Isfiya, Israel.
1.407 T
CHEK.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Check-Cap Ltd. Held Shareholder Meeting

    Check-Cap Ltd. held a shareholder meeting on November 17, 2025, where shareholders approved all merger-related proposals, allowing the merger with MBody AI to proceed.

    Reuters·
    US
    CHEK
    0.00%
    US
    MBAI
    +2.34%
    Reuters·
    US
    CHEK
    0.00%
    US
    MBAI
    +2.34%

    Check-Cap Shareholders Approve MBody AI Merger With 98% Support

    Check-Cap Ltd. shareholders have approved a merger with MBody AI Corp., with over 98% support. This merger will transform Check-Cap into a leading embodied AI company on Nasdaq, enhancing enterprise automation across various sectors. The merger is expected to close soon, pending customary conditions.

    Reuters·
    US
    CHEK
    0.00%
    US
    MBAI
    +2.34%
    Reuters·
    US
    CHEK
    0.00%
    US
    MBAI
    +2.34%

    Check-Cap Shareholders to Vote on Merger With MBody AI

    Check-Cap Ltd. (NASDAQ: CHEK) shareholders will vote on a merger with MBody AI on November 14. The merger aims to enhance the adoption of embodied artificial intelligence through the MBody AI Orchestrator™ platform, which integrates machines, sensors, and people. MBody AI has secured significant enterprise contracts and is expanding its global reach, positioning stakeholders in the growing embodied AI sector.

    Reuters·
    US
    CHEK
    0.00%
    US
    MBAI
    +2.34%
    Reuters·
    US
    CHEK
    0.00%
    US
    MBAI
    +2.34%

    Check-Cap Advances Toward Merger with MBody AI

    Check-Cap Ltd. is progressing with its merger with MBody AI, where MBody AI will become a wholly owned subsidiary. The merger aims to establish a global leader in embodied AI-driven automation, with plans for cross-listing, index inclusion, and international expansion. This partnership is expected to enhance innovation and growth in the embodied AI sector. The update emphasizes the advancements toward finalizing the merger and the anticipated benefits of the combined entity.

    Reuters·
    US
    CHEK
    0.00%
    US
    MBAI
    +2.34%
    Reuters·
    US
    CHEK
    0.00%
    US
    MBAI
    +2.34%

    Check-Cap Reschedules AGM Amid Strategic Merger with MBody AI

    Check-Cap Ltd. has rescheduled its Annual General Meeting to November 14, 2025, where shareholders will vote on a merger with MBody AI, a reverse share split, and a name change to ‘MBody AI Ltd.’ The merger aims to position Check-Cap in the growing embodied AI sector. However, Spark's analysis rates CHEK as Underperform due to financial challenges, including lack of revenue and persistent losses, despite a strong equity position. Check-Cap focuses on innovative diagnostic solutions in the medical technology industry, particularly for colorectal cancer detection.

    Tip Ranks·
    US
    CHEK
    0.00%
    US
    MBAI
    +2.34%
    Tip Ranks·
    US
    CHEK
    0.00%
    US
    MBAI
    +2.34%
    © 2025 Longbridge｜Disclaimer